Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Pegzilarginase |
Synonyms | |
Therapy Description |
Pegzilarginase (AEB1102) is a modified form of human arginase (ARG1) that metabolizes arginine and decreased levels of arginine may induce autophagy and promote apoptosis (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 869, PMID: 31954097). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Pegzilarginase | AEB1102|AEB-1102|Co-ArgI-PEG | Pegzilarginase (AEB1102) is a modified form of human arginase (ARG1) that metabolizes arginine and decreased levels of arginine may induce autophagy and promote apoptosis (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 869, PMID: 31954097). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02561234 | Phase I | Pegzilarginase | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors | Completed | USA | 0 |